The mechanisms of genetically modified vaccinia viruses for the treatment of cancer

Critical Reviews in Oncology/Hematology

Volumn 95, Issue 3, 2015, Pages 407-416

  Jefferson, Artrish ^a   Cadet, Valerie E ^a   Hielscher, Abigail ^a  

^a PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

Cancer; Oncolytic vaccinia virus; Orthopoxvirus; Virotherapy

Indexed keywords

CHEMOKINE RECEPTOR CCR4; GAG PROTEIN; GLV 1H 68; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; METHYLPREDNISOLONE SODIUM SUCCINATE; MONOCYTE CHEMOTACTIC PROTEIN 5; MYCOPHENOLATE MOFETIL; ONCOLYTIC VACCINIA VIRUS; ONCOLYTIC VIRUS; PEXASTIMOGENE DEVACIREPVEC; RANTES; TACROLIMUS; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CARCINOMATOUS PERITONITIS; DNA MODIFICATION; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; ENDOCYTOSIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; SOLID TUMOR; TUMOR CELL DESTRUCTION; TUMOR MICROENVIRONMENT; VACCINIA VIRUS; VIRUS ENTRY; APOPTOSIS; GENETICS; IMMUNOLOGY; NEOPLASMS; PATHOLOGY;

APOPTOSIS; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; VACCINIA VIRUS; VIRUS INTERNALIZATION;

EID: 84938203995     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.04.001     Document Type: Review

References (66)

1. Vaha-Koskela M.J., Heikkila J.E., Hinkkanen A.E. Oncolytic viruses in cancer therapy. Cancer Lett 2007, 254(2):178-216.
2. Sinkovics J., Horvath J. New developments in the virus therapy of cancer: a historical review. Intervirology 1993, 36(4):193-214.
3. Buller R.M., Palumbo G.J. Poxvirus pathogenesis. Microbiol Rev 1991, 55(1):80-122.
4. Kirn D.H., Thorne S.H. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 2009, 9(1):64-71.
5. Parato K.A., et al. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther 2012, 20(4):749-758.
6. Moss B. Poxvirus entry and membrane fusion. Virology 2006, 344(1):48-54.
7. Chang S.J., et al. Vaccinia mature virus fusion regulator A26 protein binds to A16 and G9 proteins of the viral entry fusion complex and dissociates from mature virions at low pH. J Virol 2012, 86(7):3809-3818.
8. Smith G.L., Vanderplasschen A., Law M. The formation and function of extracellular enveloped vaccinia virus. J Gen Virol 2002, 83(Pt 12):2915-2931.
9. Chung C.S., et al. Vaccinia virus proteome: identification of proteins in vaccinia virus intracellular mature virion particles. J Virol 2006, 80(5):2127-2140.
10. Kirn D.H., et al. Enhancing poxvirus oncolytic effects through increased spread and immune evasion. Cancer Res 2008, 68(7):2071-2075.
11. Sampath P., et al. Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects. Mol Ther 2013, 21(3):620-628.
12. Thorne S.H., et al. Rational strain selection and engineering creates a broad-spectrum: systemically effective oncolytic poxvirus, JX-963. J Clin Invest 2007, 117(11):3350-3358.
13. McCart J.A., et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 2001, 61(24):8751-8757.
14. Buller R.M., et al. Cell proliferative response to vaccinia virus is mediated by VGF. Virology 1988, 164(1):182-192.
15. Hikichi M., et al. MicroRNA regulation of glycoprotein B5R in oncolytic vaccinia virus reduces viral pathogenicity without impairing its antitumor efficacy. Mol Ther 2011, 19(6):1107-1115.
16. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116(2):281-297.
17. Johnson C.D., et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 2007, 67(16):7713-7722.
18. Johnson S.M., et al. RAS is regulated by the let-7 microRNA family. Cell 2005, 120(5):635-647.
19. Yang Q., et al. Low-level expression of let-7a in gastric cancer and its involvement in tumorigenesis by targeting RAB40C. Carcinogenesis 2011, 32(5):713-722.
20. Edge R.E., et al. A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication. Mol Ther 2008, 16(8):1437-1443.
21. Kirn D.H., et al. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med 2007, 4(12):e353.
22. Stojdl D.F., et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000, 6(7):821-825.
23. Alcami A., Symons J.A., Smith G.L. The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN. J Virol 2000, 74(23):11230-11239.
24. Clarke M.F., et al. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006, 66(19):9339-9344.
25. Power A.T., et al. Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol Ther 2007, 15(1):123-130.
26. Guo Z.S., et al. The combination of immunosuppression and carrier cells significantly enhances the efficacy of oncolytic poxvirus in the pre-immunized host. Gene Ther 2010, 17(12):1465-1475.
27. Linn Y.C., Hui K.M. Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia. Leuk Lymphoma 2003, 44(9):1457-1462.
28. Thorne S.H., Contag C.H. Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery. Gene Ther 2008, 15(10):753-758.
29. Thorne S.H., Negrin R.S., Contag C.H. Synergistic antitumor effects of immune cell-viral biotherapy. Science 2006, 311(5768):1780-1784.
30. Townsley A.C., et al. Vaccinia virus entry into cells via a low-pH-dependent endosomal pathway. J Virol 2006, 80(18):8899-8908.
31. Schmidt F.I., Bleck C.K., Mercer J. Poxvirus host cell entry. Curr Opin Virol 2012, 2(1):20-27.
32. Senkevich T.G., et al. Poxvirus multiprotein entry-fusion complex. Proc Natl Acad Sci USA 2005, 102(51):18572-18577.
33. Haga I.R., et al. TRAF2 facilitates vaccinia virus replication by promoting rapid virus entry. J Virol 2014, 88(7):3664-3677.
34. Falcone S., et al. Macropinocytosis: regulated coordination of endocytic and exocytic membrane traffic events. J Cell Sci 2006, 119(Pt 22):4758-4769.
35. Watanabe N., Mitchison T.J. Single-molecule speckle analysis of actin filament turnover in lamellipodia. Science 2002, 295(5557):1083-1086.
36. Mercer J., et al. Vaccinia virus strains use distinct forms of macropinocytosis for host-cell entry. Proc Natl Acad Sci USA 2010, 107(20):9346-9351.
37. Mercer J., Helenius A. Apoptotic mimicry: phosphatidylserine-mediated macropinocytosis of vaccinia virus. Ann NY Acad Sci 2010, 1209:49-55.
38. Mercer J., Helenius A. Virus entry by macropinocytosis. Nat Cell Biol 2009, 11(5):510-520.
39. Charras G.T., et al. Reassembly of contractile actin cortex in cell blebs. J Cell Biol 2006, 175(3):477-490.
40. Villa N.Y., et al. Myxoma and vaccinia viruses exploit different mechanisms to enter and infect human cancer cells. Virology 2010, 401(2):266-279.
41. Hiley C.T., et al. Vascular endothelial growth factor A promotes vaccinia virus entry into host cells via activation of the Akt pathway. J Virol 2013, 87(5):2781-2790.
42. Moffat B.A., et al. Inhibition of vascular endothelial growth factor (VEGF)-A causes a paradoxical increase in tumor blood flow and up-regulation of VEGF-D. Clin Cancer Res 2006, 12(5):1525-1532.
43. Semenza G.L. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 2012, 33(4):207-214.
44. Zhang Q., et al. The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivation. Mol Genet Genomics 2009, 282(4):417-435.
45. Wang H., et al. Oncolytic vaccinia virus GLV-1h68 strain shows enhanced replication in human breast cancer stem-like cells in comparison to breast cancer cells. J Transl Med 2012, 10:167.
46. Duggal R., et al. Vaccinia virus expressing bone morphogenetic protein-4 in novel glioblastoma orthotopic models facilitates enhanced tumor regression and long-term survival. J Transl Med 2013, 11(1):155.
47. Buijs J.T., et al. The BMP2/7 heterodimer inhibits the human breast cancer stem cell subpopulation and bone metastases formation. Oncogene 2012, 31(17):2164-2174.
48. Bao Z., et al. BMP4, a strong better prognosis predictor, has a subtype preference and cell development association in gliomas. J Transl Med 2013, 11:100.
49. Guse K., et al. Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models. J Virol 2010, 84(2):856-866.
50. Kaufman H.L., et al. Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J Clin Invest 2005, 115(7):1903-1912.
51. Li J., et al. Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. Mol Ther 2011, 19(4):650-657.
52. Levy J.A. The unexpected pleiotropic activities of RANTES. J Immunol 2009, 182(7):3945-3946.
53. Nishimura T., et al. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 1999, 190(5):617-627.
54. Hadrup S., Donia M., Thor Straten P. Effector CD4 and CD8 T cells and their role in the tumor microenvironment. Cancer Microenviron 2013, 6(2):123-133.
55. Li J., et al. Expression of CCL19 from oncolytic vaccinia enhances immunotherapeutic potential while maintaining oncolytic activity. Neoplasia 2012, 14(12):1115-1121.
56. Gil M., et al. Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases. Proc Natl Acad Sci USA 2013, 110(14):E1291-E1300.
57. Burger J.A., Kipps T.J. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006, 107(5):1761-1767.
58. Whilding L.M., et al. Vaccinia virus induces programmed necrosis in ovarian cancer cells. Mol Ther 2013, 21(11):2074-2086.
59. Yu F., et al. T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy. Mol Ther 2014, 22(1):102-111.
60. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100(1):57-70.
61. Castedo M., et al. Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy. Oncogene 2004, 23(25):4362-4370.
62. Hayflick L., Moorhead P.S. The serial cultivation of human diploid cell strains. Exp Cell Res 1961, 25:585-621.
63. Kim J., Klionsky D.J. Autophagy, cytoplasm-to-vacuole targeting pathway, and pexophagy in yeast and mammalian cells. Annu Rev Biochem 2000, 69:303-342.
64. Guo Z.S., et al. The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res 2005, 65(21):9991-9998.
65. Breitbach C.J., et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011, 477(7362):99-102.
66. Lauer U.Z., Sturm Martina, Koppenhoefer Julia, Bitzer Ursula, Malek Michael, Glatzle Nisar P., et al. Phase I/II clinical trial of a genetically modified and oncolytic vaccinia virus GL-ONC1 in patients with unresactable, chemotherapy-resistant peritoneal carcinomatosis. J Clin Oncol 2013, 31(15):3098. (Meeting Abstracts).